Senescent cells, which are characterized by irreversible damage and an inflammatory secretome, are considered a key driving force behind many age-related diseases. Due to a failure in immune surveillance, senescent cells accumulate and impact their local environment by inducing inflammation and promoting extracellular matrix remodeling, thus resulting in a myriad of metabolic and fibrotic consequences. Therefore, enabling the removal of senescent cells dramatically ameliorates disease pathologies in many age-related diseases, leading to overall improvements in health-span.
At Deciduous Therapeutics, we have discovered novel molecules that can activate a critical endogenous immune surveillance mechanism to selectively remove senescent cells and thereby treat several classes of age-related diseases.
At Deciduous Therapeutics, we have discovered novel molecules that can activate a critical endogenous immune surveillance mechanism to selectively remove senescent cells and thereby treat several classes of age-related diseases.
Location: United States, California, San Francisco
Employees: 11-50
Investors 4
| Date | Name | Website |
| - | Formic Ven... | formic.vc |
| - | Healthspan... | healthspan... |
| - | quadraScop... | quadrascop... |
| - | Axial VC | axialvc.co... |
Mentions in press and media 1
| Date | Title | Description |
| 27.10.2021 | Deciduous Therapeutics Announces Appointments to the Board, SAB, and Advisor Roles | SAN FRANCISCO, Oct. 27, 2021 /PRNewswire/ -- Deciduous Therapeutics, an early stage immune therapy start-up, announced today the appointment of an independent board member, additional Scientific Advisory Board members, and company advisors.... |